ArticleFrontiers in medicine2025
Intrathecal injection of bone marrow concentrate in children with autism spectrum disorder: a retrospective chart analysis.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The growing prevalence of autism spectrum disorder (ASD) underscores the urgent need for therapies that target underlying biological mechanisms, with cell-based interventions offering a potentially transformative approach by targeting core physiological disruptions rather than providing temporary symptom management. The purpose of this study was to report on our experience with an autologous cell-based intervention in children with ASD. Methods: This retrospective data analysis included pre- and postinterventional data from 128 children with ASD who received intrathecal injections of autologous bone marrow concentrate. Patient and procedure related characteristics, complications, and the Autism Treatment Evaluation Checklist (ATEC) scores were extracted from patient's medical records. Results: Data were analyzed from 128 children (27 females and 101 males), aged between two and 16 years at their first intervention. A total of 32.8% underwent more than two single-step procedures. Significant improvements from the first to the second intervention were detected in the total and all subgroup ATEC scores, as well as in the severity groups ( Conclusion: Both a significant improvement in ATEC scores, and significant severity shifts to milder forms-even into the "no symptoms" category-suggest a measurable improvement in autism-related symptoms after autologous, bone marrow derived, intrathecally applied single procedures in children with ASD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.